Show an ad over header. AMP

NYT: White House drug price negotiations between broke down over $100 "Trump Cards"

Negotiations on a deal between the White House and pharmaceutical industry to lower drug prices broke down last month after Mark Meadows, the president's chief of staff, insisted that drugmakers pay for $100 cash cards to be mailed to seniors before the election, according to the New York Times.

Why it matters: Some of the drug companies feared that in agreeing to the prescription cards — reportedly dubbed "Trump Cards" by some in the pharmaceutical industry — they would boost Trump's political standing weeks ahead of Election Day with voters over 65, a group that is crucial to the president's reelection bid, per the Times.


The other side: The White House says it did not expect to put President Trump's name on the cards.

  • Before the introduction of the cards, the White House and the pharmaceutical industry were nearing an agreement in which drug companies would spend $150 billion to address out-of-pocket consumer costs and pay co-pays that older Americans carry in Medicare’s prescription drug program.

Of note: Trump's name was added to the physical coronavirus stimulus checks approved under the CARES Act and sent to millions of Americans earlier this year.

What they're saying: “We could not agree to the administration’s plan to issue one-time savings cards right before a presidential election,” Priscilla VanderVeer, vice president of public affairs at PhRMA, the industry’s largest trade group, told the New York Times.

  • “One-time savings cards will neither provide lasting help, nor advance the fundamental reforms necessary to help seniors better afford their medicines."
  • Judd Deere, a White House spokesperson, did not comment specifically on the savings cards and noted that Trump held back issuing an executive order this summer that would have tied some drug prices to what other countries pay, also called "most-favored nation" drug pricing.

Our thought bubble, via Axios' Caitlin Owens: The “most-favored nation” executive order isn’t the worst thing to happen to the pharmaceutical industry.

  • There’s no way the regulations it calls for are implemented before the election, and the Trump administration has dropped almost every major drug policy initiative it has proposed.
  • So the industry doesn’t have to pay for reforms and doesn’t have to look like they’re trying to give Trump a giant political win right before the election, and probably doesn’t need to worry that much about the executive order either.

The norms around science and politics are cracking

Crafting successful public health measures depends on the ability of top scientists to gather data and report their findings unrestricted to policymakers.

State of play: But concern has spiked among health experts and physicians over what they see as an assault on key science protections, particularly during a raging pandemic. And a move last week by President Trump, via an executive order, is triggering even more worries.

Keep reading... Show less

Apple sets September quarter sales record despite pandemic

Apple on Thursday reported quarterly sales and earnings that narrowly exceeded analysts estimates as the iPhone maker continued to see strong demand amid the COVID-19 pandemic.

What they's saying: The company said response to new products, including the iPhone 12 has been "tremendously positive" but did not give a specific forecast for the current quarter.

Keep reading... Show less

Podcast: The vaccine race turns toward nationalism

The coronavirus pandemic is worsening, both in the U.S. and abroad, with cases, hospitalizations and deaths all rising.

Axios Re:Cap digs into the state of global vaccine development — including why the U.S. and China seem to going at it alone — with medicinal chemist and biotech blogger Derek Lowe.

How central banks can save the world

The trillion-dollar gap between actual GDP and potential GDP is a gap made up of misery, unemployment, and unfulfilled promise. It's also a gap that can be eradicated — if central banks embrace unconventional monetary policy.

  • That's the message from Eric Lonergan and Megan Greene, two economists who reject the idea that central banks have hit a "lower bound" on interest rates. In fact, they reject the idea that "interest rates" are a singular thing at all, and they fullthroatedly reject the idea — most recently put forward by New York Fed president Bill Dudley — that the Fed is "out of firepower."

Why it matters: If Lonergan and Greene are right, then central banks have effectively unlimited ammunition in their fight to increase inflation and employment. They are limited only by political will.

Keep reading... Show less

Leon Black says he "made a terrible mistake" doing business with Jeffrey Epstein

Apollo Global Management CEO Leon Black on Wednesday said during an earnings call that he made a "terrible mistake" by employing Jeffrey Epstein to work on personal financial and philanthropic services.

Why it matters: Apollo is one of the world's largest private equity firms, and already has lost at least one major client over Black's involvement with Epstein.

Keep reading... Show less

Jeremy Corbyn suspended by U.K. Labour Party over anti-Semitism report

The U.K. Labour Party has suspended its former leader, Jeremy Corbyn, after a watchdog report found that the party failed to properly take action against allegations of anti-Semitism during his time in charge.

Why it matters: It represents a strong break by Keir Starmer, Labour's current leader, from the Corbyn era and one of the party's most persistent scandals.

Keep reading... Show less

U.S. economy sees record growth in third quarter

The U.S. economy grew at a 33.1% annualized pace in the third quarter, the Commerce Department said on Thursday.

The state of play: The record growth follows easing of the coronavirus-driven lockdowns that pushed the economy to the worst-ever contraction — but GDP still remains well below its pre-pandemic level.

Keep reading... Show less

Investors have nowhere to hide

The massive losses in oil prices and U.S. and European equities were not countered by gains in traditional safe-haven assets on Wednesday.

Why it matters: The unusual movement in typical hedging tools like bonds, precious metals and currencies means they are not providing investors an asset that will appreciate in the event of a major equity selloff.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories